Faes Farma
Faes Farma, one of the leading Spanish pharmaceutical groups, is dedicated to research, development, manufacturing, and marketing of prescription drugs, and healthcare and animal nutrition products. We’re organised into two business areas: Pharma & Healthcare and FARM Faes.
In our 90-year history, we’ve established ourselves as an international group with a presence across five continents and in over 130 countries, through either direct sales or licensed products.
Our global footprint
Mapa Mundial
Presence through subsidiaries
Presence via direct marketing or partners
Medium-term target markets
Pharma & Healthcare: Our strategy
At Faes Farma, our Pharma & Healthcare business focuses on new drug research and the continuous search for new products to enhance our portfolio, offering a broad and diversified proposition.
We research, manufacture, and market prescription drugs. We develop and market OTC products (cosmetics, supplements, and nutritional products, as well as medical devices for human use).
For running our business, we have 3 pharmaceutical production plants and another under construction, expected to commence operations in early 2024.
The three main molecules that we market are: bilastine (for allergic rhinoconjunctivitis), calcifediol (vitamin D), and mesalazine (for ulcerative colitis). Our growth strategy involves various approaches: direct marketing, licensing, and operating as a contract manufacturing organisation (CMO).
Faes Farma has achieved a key national and international positioning in the direct marketing of its own and third-party products, and we have become a successful commercial partner. This activity is carried out from our main headquarters in Spain and the group’s subsidiaries in Portugal, Italy, Nigeria, United Arab Emirates, Colombia, Chile, Ecuador, Guatemala, Mexico, and Peru. Strategic partnerships further our reach globally.
We’re making our presence felt in three main regions worldwide: Iberia, our springboard for a well-established business; Latam, where we’re present in key markets; and the Middle East and Africa, encompassing over 40 countries with plans for sustained long-term growth.
Our products, available in more than 130 countries, cater to a range of therapeutic needs – respiratory, cardiovascular, digestive, metabolic, and locomotor, to name a few.
One of the fundamental pillars of Faes Farma in identifying opportunities that contribute to the value, sustainability, growth, and development of the business is the out-licensing of proprietary product licenses. These initiatives drive the company’s commercial activity, optimizing the value of our innovative, generic, and OTC products, as well as our manufacturing assets.
Currently, we have licensees in more than 170 countries. Our out-licensing agreements provide them with an opportunity to strengthen their therapeutic offering in less time and with lower investment, thus optimizing their current resources. For us, these agreements offer the possibility of bringing our products to markets where Faes Farma does not have a direct presence.
The main areas of focus in our R&D activities include allergy, vitamin D deficiency, ulcerative colitis, muscle relaxants, corticosteroids, and more. Thanks to this wide range of projects, we can offer various licensing opportunities and have sufficient flexibility to engage with both highly developed and demanding agencies as well as small companies in emerging markets.
At Faes Farma, we assist in unlocking the full potential of your project.
- With over 90 years of experience in pharmaceutical manufacturing.
- A new manufacturing facility spanning over 60,000m2, equipped with the latest technology and capable of producing 117 million units annually.
- Innovative pharmaceutical forms (liquid monodoses -sticks, unifill-, soft gel capsules, bilayer tablets, etc.) and traditional forms (solids, liquids, topicals, and suppositories) tailored to the specific needs of our clients.
- Manufacturing processes adaptable to different scales and volumes.
- Technologies and processes focused on agile and successful analytical and technological transfers.
- Pilot plant.
- Regulatory support throughout the product life cycle.
- Comprehensive quality assurance and compliance with the highest standards (we manufacture for over 130 countries).
- Dedicated work teams.
Our CDMO services encompass all activities necessary for the successful execution of your project, from development to launch. Our unwavering commitment to quality and innovation allows us to provide our clients with the flexibility and quality they seek for their products, as well as the reliability and agility they need for their CDMO projects.
In addition to marketing its own innovative products, Faes Farma has an extensive and very successful history of launching products from other laboratories, both prescription drugs in all our subsidiaries and OTC products in Iberia.
What makes us different and allows us to achieve long-term agreements comes directly from the fundamental values of Faes Farma:
– A rigorous selection of products that can add value to patients or clients
– A mutual commitment without fail with our partners
– A long-term vision of the projects
– A dedication from everyone so that the ingredients are brought together to bring out the best potential of the active ingredients
Within the areas of interest, our focus – for all our subsidiaries – is primarily on prescription products that provide incremental added value to patients or are completely novel.
Our focus is on the specialties that we visit with our products in our portfolio (ENT, pediatrics, Pulmonology, Allergy, Gynecology, Rheumatology, Endocrinology, Urology, Gastroenterology,…). However, we are an agile laboratory with a very powerful “track record” of launches in new areas (Diabetes, Central nervous system,…).
At Iberia, we are also part of the leaders in the OTC sector and are a reference partner for well-established brands that want to go to the next level or for new innovative products, whether medicines or medical devices.
Among our partners, we have large multinationals such as GSK, Kyorin, Zeria pharmaceuticals, Norgine, but also smaller laboratories with differentiating products.
FARM Faes: Our strategy
We create high-quality nutritional solutions and strategies to enhance the health and well-being of livestock animals: pigs, ruminants, poultry, and aquaculture.
We’re committed to sustainable animal production to feed the world, aiming to provide high-quality animal protein with the utmost eco-efficiency.
We operate three factories for the production of nutritious animal feed, with a new plant under construction for 2024.
